Copertina

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yuki Teramoto, Ying Wang, Hiroshi Miyamoto
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	BJUI Compass
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
di: Muhammad Imran, et al.
Pubblicazione: (2026)

The carbon footprint of transperineal prostate biopsy
di: Daniel A. Carson, et al.
Pubblicazione: (2025)

Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
di: Maxwell Louis Sandberg, et al.
Pubblicazione: (2026)

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
di: Esther H. J. Hamoen, et al.
Pubblicazione: (2025)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
di: Stijn M. van den Bosch, et al.
Pubblicazione: (2026)

Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
di: Agnieszka Krzyzanowska, et al.
Pubblicazione: (2024)

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review
di: Abel Tesfai, et al.
Pubblicazione: (2024)

Risk factors of negative prostate biopsies: A CHAID decision tree analysis
di: Pierre Allainguillaume, et al.
Pubblicazione: (2026)

Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta‐analysis
di: Sean Lim, et al.
Pubblicazione: (2024)

Cost‐effectiveness analysis of a biopsy‐free diagnostic strategy for prostate cancer using mpMRI and PSMA‐PET/CT
di: Joshua Yi Min Tung, et al.
Pubblicazione: (2026)

The impact of biopsy core length on the discrepancy in Gleason scores between biopsy and radical prostatectomy specimen
di: Cheng‐hao Guo, et al.
Pubblicazione: (2025)

First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
di: See‐Tong Pang, et al.
Pubblicazione: (2025)

Transperineal prostate biopsy with freehand technique under local anaesthetic: A systematic review and meta‐analysis
di: Benjamin M. Mac Curtain, et al.
Pubblicazione: (2025)

Concordance with final pathology when transitioning from standard transrectal to cognitive targeted transperineal prostate biopsy
di: Alfred Honoré, et al.
Pubblicazione: (2025)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
di: Eric Margolis, et al.
Pubblicazione: (2025)

A modified Delphi consensus statement on the role of biopsy in small renal masses
di: Darryl E. Bernstein, et al.
Pubblicazione: (2025)

Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology
di: Mitchell M. Huang, et al.
Pubblicazione: (2025)

Multivariable model integrating PHI and mpMRI for detecting csPCa in biopsy‐naïve men
di: Mario Dominguez Esteban, et al.
Pubblicazione: (2025)

Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
di: Serdar Turan, et al.
Pubblicazione: (2025)

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
di: Abel Tesfai, et al.
Pubblicazione: (2024)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
di: Alan Priester, et al.
Pubblicazione: (2024)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
di: Jennifer Dunsmore, et al.
Pubblicazione: (2024)

Real‐world use of maintenance bacillus Calmette‐Guérin therapy in patients with non‐muscle‐invasive bladder cancer in Japan: ASUKA study
di: Makito Miyake, et al.
Pubblicazione: (2025)

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
di: Mohammadmehdi Adhami, et al.
Pubblicazione: (2026)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
di: Nicole Handa, et al.
Pubblicazione: (2025)

Emerging tools for the early detection of prostate cancer
di: Muhammad Haider, et al.
Pubblicazione: (2025)

Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
di: Sophia M. Abusamra, et al.
Pubblicazione: (2025)

Increased risk of bleeding during and after HoLEP in patients with prostate cancer: A multicentre comparative cohort study
di: Angelo Porreca, et al.
Pubblicazione: (2025)

Bibliometric analysis of focal therapy in prostate cancer research
di: Mohammed Shahait, et al.
Pubblicazione: (2024)

Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
di: Georgios Daouacher, et al.
Pubblicazione: (2026)

Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
di: Rachel Weng, et al.
Pubblicazione: (2025)

Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?
di: Thomas Philip Cahill, et al.
Pubblicazione: (2024)

Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
di: Ailene E. Corona, et al.
Pubblicazione: (2026)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
di: Arjun Pon Avudaiappan, et al.
Pubblicazione: (2024)

National survey of urologists' views on prostate cancer screening in the United Kingdom
di: Nikhil Mayor, et al.
Pubblicazione: (2026)

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
di: Eric V. Li, et al.
Pubblicazione: (2024)

Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
di: Nadia Rokan, et al.
Pubblicazione: (2025)

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
di: Ruth Pidsley, et al.
Pubblicazione: (2024)

Long‐term outcome of transurethral laser ablation for recurrent non‐muscle invasive bladder cancer: An EORTC risk‐matched study
di: Chase Peng Yun Ng, et al.
Pubblicazione: (2025)

Incorporating the NICE Cambridge Prognostic Groups and Predict Prostate into a structured informed‐decision making clinic reduces over‐treatment rates of early prostate cancer
di: Vincent J. Gnanapragasam, et al.
Pubblicazione: (2025)